Series A round by Biohaven brings in $80mm for CNS pipeline development; later adds $20mm

Biohaven Pharmaceuticals Holding Co. Ltd. (orphan neurologic disease candidates) raised $80mm in a Series A preferred round led by Venrock, which was joined by RA Capital Management, Vivo Capital, Aisling Capital, Rock Springs Capital, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations, Litmore Capital, and board members John W. Childs and Greg Bailey, MD (who is also the company’s SVP, business development). Cowen & Co. and William Blair were co-placement agents. Prior to this round, the company brought in about $20mm in financing.